索利吉克斯公司美股招股说明书(2026-01-23版)

COMMON STOCK We have entered into an At Market Issuance Sales Agreement (the “sales agreement”) with Rodman & Renshaw LLC(“Rodman” or the “sales agent”), dated January23, 2026, relating to shares of our common stock, par value $0.001 per share,offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreementand this prospectus supplement and the accompanying prospectus, we may offer and sell shares of our common stock having anaggregate offering price of up to $3,450,000 from time to time through Rodman as our sales agent. This prospectus supplement Our common stock is traded on The Nasdaq Capital Market under the symbol “SNGX”. On January20, 2026, the lastreported closing sales price of our common stock on The Nasdaq Capital Market was $1.38 per share. Sales of shares of our common stock, if any, under this prospectus supplement and the accompanying prospectus, may bemade by any method permitted by law deemed to be an “at-the-market offering” as defined in Rule415 promulgated under theSecurities Act of 1933, as amended (the “Securities Act”), including sales made directly on The Nasdaq Capital Market, thetrading market for our common stock, or any other existing trading market in the United States for our common stock, salesmade to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiatedprices. Rodman is not required to sell any certain number of shares or dollar amount of our common stock, but will act as a sales We are a “smaller reporting company” under the federal securities laws and, as such, are subject to reduced public companydisclosure standards for this prospectus supplement and future filings. See the section entitled “Summary — Implications ofBeing a Smaller Reporting Company” for additional information. The aggregate market value of our outstanding shares of common stock held by non-affiliates as of the date of thisprospectus supplement was $16,616,045, which was calculated based on 10,070,330 shares of outstanding common stock heldby non-affiliates as of such date, and the last reported closing price per share of $1.65 on December12, 2025. Pursuant toGeneral Instruction I.B.6 of FormS-3, in no event will we sell securities registered on this registration statement in a publicprimary offering with a value exceeding more than one-third of the aggregate market value of our voting and non-voting Investing in our common stock involves risks. Before buying any shares, you should read the discussion of material risks ofinvesting in our common stock in the section titled “Risk Factors” beginning on pageS-7of this prospectus supplement, theaccompanying prospectus and in the risks discussed in the documents incorporated by reference in this prospectus supplement andthe accompanying prospectus. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of thesesecurities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The compensation to the sales agent for sales of common shares will be up to 3.0% of the gross sales price of all shares ofcommon stock sold through the sales agent from time to time under the sales agreement. In connection with the sale of commonstock on our behalf, the sales agent will be deemed to be an “underwriter” within the meaning of the Securities Act, and thecompensation of the sales agent will be deemed to be underwriting commissions or discounts. See “Plan of Distribution”beginning on page S-[•] of this prospectus supplement for additional information regarding the sales agent’s compensation. Wehave also agreed to provide indemnification and contribution to the sales agent with respect to certain liabilities, including Rodman & Renshaw LLC Prospectus Supplement dated January23, 2026. PageABOUT THIS PROSPECTUS SUPPLEMENTS-1SUMMARYS-3THE OFFERINGS-5RISK FACTORSS-7CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRYDATA AND MARKET INFORMATIONS-12USE OF PROCEEDSS-14DIVIDEND POLICYS-14DESCRIPTION OF SECURITIESS-14PLAN OF DISTRIBUTIONS-14LEGAL MATTERSS-16EXPERTSS-16WHERE YOU CAN FIND MORE INFORMATIONS-16INCORPORATION OF CERTAIN INFORMATION BY REFERENCES-16 You should rely only on the information contained in or incorporated by reference into this prospectussupplement, the accompanying prospectus, or any free writing prospectus that we have authorized for use inconnection with this offering. Neither we nor Rodman have authorized any other person to provide you withdifferent or additional information. If anyone provides you with different or additional information, you shouldnot rely on it. Neither we nor Rodman take any responsibility for, and can provide no assurances as to thereliability of, any other information that others may give you. This prospectus supplement and theaccompanying prospectus are not offers to sell, nor